The estimated Net Worth of J Kevin Buchi is at least $10.5 millió dollars as of 10 May 2024. Mr. Buchi owns over 76,453 units of Dicerna Pharmaceuticals Inc stock worth over $10,016,392 and over the last 12 years he sold DRNA stock worth over $0. In addition, he makes $505,373 as Independent Chairman of the Board at Dicerna Pharmaceuticals Inc.
J has made over 12 trades of the Dicerna Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 76,453 units of DRNA stock worth $2,922,034 on 10 May 2024.
The largest trade he's ever made was exercising 80,128 units of Dicerna Pharmaceuticals Inc stock on 9 May 2023 worth over $3,062,492. On average, J trades about 12,814 units every 118 days since 2013. As of 10 May 2024 he still owns at least 262,072 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Mr. Buchi stock trades at the bottom of the page.
J. Kevin Buchi is Independent Chairman of the Board of the Company. Mr. Buchi served as CEO and a director of Biospecifics Technologies Corp. (NASDAQ: BSTC) from October 2019 until April 2020. Mr. Buchi served as Impax Laboratories, LLC’s Interim President and Chief Executive Officer from December 2016 until March 2017 and as member of the Impax Board of Directors from November 2016 until the completion of the combination of Impax and Amneal Pharmaceuticals (NYSE: AMRX). Mr. Buchi served as President and Chief Executive Officer of TetraLogic Pharmaceuticals (formerly NASDAQ: TLOG) from August 2013 to December 2016. Before TetraLogic, he served as Corporate Vice President of Global Branded Products at Teva Pharmaceutical Industries Limited (NYSE: TEVA) from 2011 to May 2012. Mr. Buchi was Chief Executive Officer of Cephalon, Inc. (formerly NASDAQ: CEPH), which was acquired by Teva Pharmaceutical Industries Limited in October 2011. In addition, Mr. Buchi currently serves as a director of Amneal Pharmaceuticals Inc. (NYSE: AMRX) and Benitec Biopharma Ltd. (NASDAQ: BNTC). Mr. Buchi previously served on the Board of Directors of EPIRUS Biopharmaceuticals, Inc. (formerly NASDAQ: EPRS) from June 2013 to July 2016, Alexza Pharmaceuticals, Inc. (formerly NASDAQ: ALXA) from January 2013 to June 2016, Forward Pharma A/S (NASDAQ: FWP) from December 2012 to May 2016, and Stemline Therapeutics, Inc. (NASDAQ: STML) from March 2012 to May 2016. Mr. Buchi received his B.A. degree in Chemistry from Cornell University and a Masters of Management degree from the J.L. Kellogg Graduate School of Management, Northwestern University. The Nominating and Corporate Governance Committee believes that Mr. Buchi’s scientific and business expertise, including his diversified background as an executive officer and director in biopharmaceutical companies, provide him with the qualifications and skills to serve as a member of our Board of Directors.
As the Independent Chairman of the Board of Dicerna Pharmaceuticals Inc, the total compensation of J Buchi at Dicerna Pharmaceuticals Inc is $505,373. There are 4 executives at Dicerna Pharmaceuticals Inc getting paid more, with Douglas Fambrough having the highest compensation of $5,048,130.
J Buchi is 65, he's been the Independent Chairman of the Board of Dicerna Pharmaceuticals Inc since 2019. There are 2 older and 11 younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.
J's mailing address filed with the SEC is C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER, NJ, 08807.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo és Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: